Visium, a prominent player in the AI and data sector for regulated industries, has successfully completed its first institutional funding round, attracting support from top-tier investors and notable unicorn founders.
Based in Lausanne, Switzerland, Visium has rapidly expanded since its inception in 2018, now employing 100 AI specialists and offering over 250 solutions to major clients in the life sciences sector, including Roche and Novartis. The recent funding round was co-led by Columbus Venture Partners and Concentric, with participation from a select group of influential angel investors. While the specific amount raised remains undisclosed, this financial boost is aimed at accelerating Visium's growth in Europe and the U.S., enhancing its product offerings and team capabilities.
Columbus Venture Partners, known for its focus on biotechnology and life sciences, and Concentric, which invests in transformative software-driven businesses, see Visium as a pivotal player in the ongoing integration of generative AI within pharmaceutical and biotech operations. Investors believe that Visium's innovative approach can streamline drug development processes and drive data-driven decision-making across the industry.
As Visium prepares for its next phase, it is also strengthening its governance by appointing new members to its Board of Directors and Advisory Board, including industry veterans from QuantumBlack and former executives from leading pharma and biotech firms. This strategic alignment with experienced operators is expected to enhance Visium's capabilities as it continues to navigate the complexities of AI implementation in regulated environments.